Caricamento...

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy

BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Inflamm Bowel Dis
Autori principali: Huang, Vivian W., Prosser, Connie, Kroeker, Karen I., Wang, Haili, Shalapay, Carol, Dhami, Neil, Fedorak, Darryl K., Halloran, Brendan, Dieleman, Levinus A., Goodman, Karen J., Fedorak, Richard N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://ncbi.nlm.nih.gov/pubmed/25989340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000000376
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !